Angina Pectoris Drugs Market Analysis and Comparison by end-user To 2022
Global Angina Pectoris Drugs Market study includes In-depth Analysis of the market by latest technologies, trends, opportunities, challenges, key players and business strategies considering types, segment, and future analysis. The Angina Pectoris Drugs Market Report Provides Growth History, Sales Channel, Manufacturers Profiled in Angina Pectoris Drugs Business, Market Share of Product, Application and Regional Scope of Angina Pectoris Drugs which makes the research report a helpful resource for marketing people, forecasters, industry executives & consultants, sales, product managers, Strategy Advisor, potential investors to understand the present as well as future market size, situations in terms of growth rate and revenue. This report will help the viewer in Better Decision Making.
Global Angina Pectoris Drugs Market is estimated to reach
USD 10.6 billion by 2022 owing to the rising number of patients suffering from
angina pectoris and the probable acceptance of modern therapies like
varespladib and Generx that are in late stage of clinical development. If these
modern therapies are approved, they are expected to contribute impressively to
the growth of angina pectoris drugs industry since they will be sold at premium
prices by manufacturing companies.
Get a Sample Copy
of This Report @ https://www.millioninsights.com/industry-reports/angina-pectoris-drugs-market/request-sample
When chest pain (angina) occurs, physicians suggest
blockages in heart arteries. There are many types of angina one may have, but
the major ones are chronic stable angina that occurs when the heart is working
steadily and the unstable angina which occurs when the chest pain gets worse.
The other types comprise variant angina and microvascular angina. At present,
angina pectoris treatments are not comparatively effective and therefore
newbies are experiencing new opportunities to introduce more effective
therapies and contribute the growth of angina pectoris drugs market.
The rise in chronic diseases is one of the major growth
factors for the growth of angina pectoris drugs industry. Angina Pectoris is
mainly caused by growing prevalence of chronic diseases like high blood
pressure, diabetes and obesity. High blood pressure and diabetes are likely to
develop more serious health issues associated with numerous important organs.
Obesity is the main reason for fatal cardiac disorders irrespective of the
person is suffering from high blood pressure or diabetes. The increasing
geriatric population is also projected to encourage the demand for angina
pectoris drugs in the forecast period.
(β-blockers) β-Adrenoceptor antagonists are suggested for
the first line treatment of heart failure, arterial fibrillation, coronary
artery disease and hypertension with heart failure, angina pectoris, or prior
myocardial infarction. β-Blocker therapy is also used in asymptomatic patients
with large areas of ischemia (level IIa C evidence) and in microvascular angina
to recover effort-related angina symptoms. A research revealed that chronic
stable angina affects very less population in the western countries with an
anticipated yearly risk of death and non-fatal myocardial infraction of
comparatively less population.
Angina pectoris drugs market is categorized on the basis
of drug class, end-users, and geography. On the basis of drug class, the market
is divided into Angiotensin-converting enzyme inhibitors, Beta-adrenergic
blocking agents, Calcium channel blockers, Short & Long – acting
Nitroglycerines, Anti-ischemic agents and Antiplatelet agents. In terms of
end-users, angina pectoris drugs industry is segmented as retail pharmacies,
hospital pharmacies and online pharmacies.
Geographically, angina pectoris drugs market is segmented
as Asia Pacific, North America, Europe, South America, and Middle East &
Africa. North America is expected to dominate the market owing to high
prevalence of chronic disorders and improved healthcare infrastructure.
The prominent players in angina pectoris drugs industry
comprise Astellas Pharma, AstraZeneca PLC, Ark Therapeutics Group plc, Cardium
Therapeutics, Cardeus Pharmaceuticals, CardioVascularBioTherapeutics (CVBT),
HUYA Bioscience International LLC, Bristol-Myers Squibb Company, F. Hoffmann-La
Roche Ltd, Korea Otsuka Pharmaceutical Co.Ltd, Pfizer, Inc., Baxalta US Inc.,
Gilead Sciences, Inc, Sanofi SA, and TSH Biopharm Corporation Limited.
Chapter 1 Angina
Pectoris Drugs Market Overview
1.1 Angina
Pectoris Drugs Definition
1.2 Angina
Pectoris Drugs Market Size Status and Outlook (2014-2025)
1.3 Global Angina
Pectoris Drugs Market Size Comparison by Region (2014-2025)
1.4 Global Angina
Pectoris Drugs Market Size Comparison by Type (2014-2025)
1.5 Global Angina
Pectoris Drugs Market Size Comparison by Application (2014-2025)
1.6 Global Angina
Pectoris Drugs Market Size Comparison by Sales Channel (2014-2025)
1.7 Angina
Pectoris Drugs Market Dynamics
1.7.1 Market
Drivers/Opportunities
1.7.2 Market
Challenges/Risks
1.7.3 Market News
(Mergers/Acquisitions/ Expansion)
Chapter 2 Angina
Pectoris Drugs Market Segment Analysis by Player
Chapter 3 Angina
Pectoris Drugs Market Segment Analysis by Type
And Continue…
Know More Insights @ https://latestmarketstudy.wordpress.com
Comments
Post a Comment